[go: up one dir, main page]

AU2001296000A1 - Nateglinide-containing hydrophilic drug preparations - Google Patents

Nateglinide-containing hydrophilic drug preparations

Info

Publication number
AU2001296000A1
AU2001296000A1 AU2001296000A AU9600001A AU2001296000A1 AU 2001296000 A1 AU2001296000 A1 AU 2001296000A1 AU 2001296000 A AU2001296000 A AU 2001296000A AU 9600001 A AU9600001 A AU 9600001A AU 2001296000 A1 AU2001296000 A1 AU 2001296000A1
Authority
AU
Australia
Prior art keywords
nateglinide
preparation
containing hydrophilic
hydrophilic drug
drug preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296000A
Other languages
English (en)
Inventor
Chisato Makino
Nobutaka Ninomiya
Akira Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of AU2001296000A1 publication Critical patent/AU2001296000A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001296000A 2000-10-24 2001-10-23 Nateglinide-containing hydrophilic drug preparations Abandoned AU2001296000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000324374 2000-10-24
JP2000-324374 2000-10-24
PCT/JP2001/009292 WO2002040010A1 (fr) 2000-10-24 2001-10-23 Preparations de medicament contenant du nateglinide

Publications (1)

Publication Number Publication Date
AU2001296000A1 true AU2001296000A1 (en) 2002-05-27

Family

ID=18801919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296000A Abandoned AU2001296000A1 (en) 2000-10-24 2001-10-23 Nateglinide-containing hydrophilic drug preparations

Country Status (19)

Country Link
US (1) US20040029968A1 (fr)
EP (1) EP1334721B1 (fr)
JP (3) JPWO2002040010A1 (fr)
KR (1) KR100829410B1 (fr)
CN (1) CN100531730C (fr)
AT (1) ATE429217T1 (fr)
AU (1) AU2001296000A1 (fr)
BR (1) BR0114897A (fr)
CA (1) CA2426764C (fr)
CY (1) CY1110320T1 (fr)
DE (1) DE60138476D1 (fr)
DK (1) DK1334721T3 (fr)
ES (1) ES2321911T3 (fr)
MX (1) MXPA03003686A (fr)
PT (1) PT1334721E (fr)
RU (1) RU2283104C2 (fr)
SI (1) SI1334721T1 (fr)
TW (1) TWI289461B (fr)
WO (1) WO2002040010A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1616561B1 (fr) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Composition antidiabetique pour administration orale
ES2307653T3 (es) * 2000-10-24 2008-12-01 Ajinomoto Co., Inc. Preparaciones que contienen nateglinida.
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005020979A1 (fr) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Procede de preparation de compositions pharmaceutiques a base de nateglinide
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2005092319A1 (fr) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Compositions pharmaceutiques a desintegration rapide, comprenant du nateglinide et un delitant
WO2005094812A1 (fr) * 2004-04-01 2005-10-13 Ajinomoto Co., Inc. Préparation contenant du natéglinide
WO2009038770A2 (fr) * 2007-09-20 2009-03-26 University Of Massachusetts Cvip Neurotoxine botulique recombinante détoxifiée
WO2013066278A1 (fr) * 2011-11-03 2013-05-10 Mahmut Bilgic Procédé de fabrication de formulations pharmaceutiques comprenant du natéglinide
WO2013115740A1 (fr) * 2012-01-31 2013-08-08 Mahmut Bilgic Combinaison synergique contenant un dérivé de méglitinide et de l'acide lipoïque
CA3176569A1 (fr) * 2020-03-27 2021-09-30 Pfizer Inc. Traitement du diabete de type 2 ou de l'obesite ou du surpoids avec de l'acide 2-[(4-{6-[(4-cyano-2-fluorobenzyl) oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl ]-1h-benzimidazole-6-carboxylique ou un sel pharmaceutiquement acceptable correspondant

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066532B2 (ja) * 1983-09-29 1994-01-26 日産化学工業株式会社 親水性コロイドにより変性したワックス性微粉末
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5474989A (en) * 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69217762T2 (de) * 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
JPH0696517B2 (ja) * 1993-03-17 1994-11-30 日産化学工業株式会社 変性したワックス性微粉末で被覆された薬剤及びその製造法
JP2994956B2 (ja) * 1994-05-31 1999-12-27 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース、その組成物およびその錠剤
KR100343062B1 (ko) * 1996-11-15 2002-07-02 에가시라 구니오 정제 조성물
CA2216215A1 (fr) * 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
JP3591801B2 (ja) * 1997-06-19 2004-11-24 田辺製薬株式会社 口腔内速崩壊性製剤の製法
JP2000178183A (ja) * 1998-12-17 2000-06-27 Lion Corp 固形製剤及びその製造方法
JP2000290171A (ja) * 1999-04-06 2000-10-17 Eisai Co Ltd 崩壊のはやい錠剤又はその製造方法
EP1616561B1 (fr) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Composition antidiabetique pour administration orale
KR100873585B1 (ko) * 2000-03-17 2008-12-11 아지노모토 가부시키가이샤 당뇨병성 합병증용 약제
PT1334963E (pt) * 2000-10-18 2007-09-20 Ajinomoto Kk Processo para a produção de cristais de nateglinida
RU2287520C2 (ru) * 2000-10-18 2006-11-20 Адзиномото Ко., Инк. Способ получения ацилфенилаланинов
ES2307653T3 (es) * 2000-10-24 2008-12-01 Ajinomoto Co., Inc. Preparaciones que contienen nateglinida.
CA2426745C (fr) * 2000-10-24 2009-09-15 Ajinomoto Co., Inc. Procede de production de cristaux de nateglinide a forme b
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration

Also Published As

Publication number Publication date
JP2013064018A (ja) 2013-04-11
KR20030042028A (ko) 2003-05-27
BR0114897A (pt) 2003-08-12
KR100829410B1 (ko) 2008-05-15
TWI289461B (en) 2007-11-11
DK1334721T3 (da) 2009-07-06
MXPA03003686A (es) 2004-01-26
JPWO2002040010A1 (ja) 2004-06-03
CN1482904A (zh) 2004-03-17
CA2426764A1 (fr) 2003-04-23
EP1334721A4 (fr) 2005-11-02
CN100531730C (zh) 2009-08-26
JP2010095551A (ja) 2010-04-30
US20040029968A1 (en) 2004-02-12
SI1334721T1 (sl) 2009-08-31
RU2283104C2 (ru) 2006-09-10
CA2426764C (fr) 2010-04-20
PT1334721E (pt) 2009-06-01
ATE429217T1 (de) 2009-05-15
EP1334721A1 (fr) 2003-08-13
DE60138476D1 (de) 2009-06-04
JP5673972B2 (ja) 2015-02-18
ES2321911T3 (es) 2009-06-15
EP1334721B1 (fr) 2009-04-22
CY1110320T1 (el) 2015-01-14
WO2002040010A1 (fr) 2002-05-23
JP5278708B2 (ja) 2013-09-04

Similar Documents

Publication Publication Date Title
CY1110320T1 (el) Παρασκευασματα υδροφιλου φαρμακου περιεχοντα νατεγλινιδη (nateglinide)
ES2402544T3 (es) Preparación pelicular rápidamente soluble
KR100890180B1 (ko) 경구투여제 및 경구투여제 유지체
US5102666A (en) Calcium polycarbophil controlled release composition and method
CA2321267A1 (fr) Forme galenique s'administrant par voie orale, a liberation immediate et prolongee, et comprenant un agent favorisant l'absorption et utilisation de cet agent
WO2002045684A3 (fr) Composition pharmaceutique a dispersion rapide
CA2413334A1 (fr) Interleukine 2 stabilisee
EP1243269A3 (fr) Formulaitons d'opioides à libération prolongée et contrôlée
AU1301199A (en) Drug delivery systems utilizing liquid crystal structures
CA2386690A1 (fr) Sels pharmaceutiques de tramadol
BR9609663A (pt) Formulações para desprendimento controlado de medicamentos fracamente soluveis
CA2237306A1 (fr) Supports d'administration pour medicaments analgesiques, anti-inflammatoires et antipyretiques contenant de l'oxyde nitreux et compositions pharmaceutiques contenant ces supports et ces medicaments
CA2015536A1 (fr) Formule pharmaceutique
ES2403069T3 (es) Composición oral de liberación controlada que contiene levetiracetam
CA2419993A1 (fr) Preparation de compositions pharmaceutiques a utiliser avec des formulations gelatineuses molles
CA2215327A1 (fr) Formulations pour composes lipophiles
EP0350701A3 (fr) Compositions pharmaceutiques pour administration orale à activités analgésiques et anti-inflammatoire, possédant un goût excellent et étant dépourvues d'effets irritants sur les membranes muqueuses
CA2377174A1 (fr) Formes galeniques orales servant a administrer une combinaison fixe de tramadol et de diclofenac
RU2003111949A (ru) Гидрофильный фармацевтический препарат, содержащий натеглинид
DE69119217T2 (de) Zusammensetzungen zur kontrollierten freigabe
US20030064101A1 (en) Floating osmotic device for controlled release drug delivery
CA2383212A1 (fr) Dosage oral a liberation regulee destine a l'administration orale
CA2340898A1 (fr) Traitement d'infections intracellulaires et compositions a cet effet
AR003131A1 (es) Preparados de liberacion controlada en multiples particulas a base de una sal potasica alcalinizante activa adecuado para producir una forma farmaceuticaoral y comprimidos obtenidos.
EP0916621A3 (fr) Eau avec un meilleur pouvoir dispersant d'huile et de graisses